Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Medtronic Advances Minimally Invasive Lung Cancer Diagnosis With New Interventional Lung Biopsy System

Executive Summary

With the recent FDA approval of Medtronic's GenCut core biopsy system, the company is moving closer to its vision of diagnosing and treating lung cancer with a completely non-invasive, outpatient solution. GenCut is specifically designed for the unique challenges of lung biopsy/sampling lung lesions and allows physicians to capture larger pieces of lung tissue to be preserved for more in-depth and accurate testing and personalized care when used during bronchoscopy procedures.

Advertisement

Related Content

New Product Briefs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register